FDA postpones Novo-approval once again
Registration applications for Novo Nordisk’s ultra-long-acting insulin analogs will be discussed at an FDA-meeting in November.
After the 8th of November Novo Nordisk will know a lot more about the commercial potential of their ultra-long-acting insulin analogs, as FDA has scheduled a meeting in the advisory committee to discuss the drugs Degludec (Tresiba) and Degludecplus.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
